Allele-Selective RNAi via CAG Mismatched Oligonucleotides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selectively inhibiting mutant Huntingtin Disease (HD) protein expression often indiscriminately target both mutant and wild-type proteins, leading to significant side effects due to the essential role of Huntingtin in normal cellular functions, and the variability of single nucleotide differences or deletions between patients complicates allele-specific RNAi applications.
Innovation Solution
The use of double-stranded RNAs that target expanded CAG repeat regions with 1 to 5 base mismatches, specifically designed to selectively inhibit mutant Huntingtin or ataxin proteins by contacting cells with 15-30 base RNAs that contain chemically modified bases and no more than one base mismatch in the seed sequence, achieving selective inhibition with a selectivity of 5-fold to 40-fold.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fully-complementary antisense oligonucleotides or siRNAs are used to reduce HTT expression, then mutant HTT protein production is inhibited, but wild-type HTT expression is also inhibited causing significant side effects
Solution Approach 1:
The patent introduces base mismatches at specific positions within the CAG repeat region of the oligonucleotide sequence. These localized modifications create differential binding affinity: the mismatched oligonucleotides bind strongly to mutant HTT mRNA (with expanded CAG repeats) but bind weakly or not at all to wild-type HTT mRNA (with normal CAG repeats). This local quality change in the oligonucleotide sequence enables selective inhibition of the mutant allele while preserving wild-type allele function, thereby achieving therapeutic effect without the harmful side effects of wild-type inhibition.
2Manufacturing precision
If siRNAs targeting single nucleotide differences or deletions are used, then allele-specific inhibition is achieved, but patient variability complicates clinical application
Solution Approach 1:
The patent designs oligonucleotides that target the CAG repeat region, which is the common pathological feature across all Huntington's disease patients regardless of their specific genetic background. By focusing on the expanded repeat tract rather than patient-specific single nucleotide polymorphisms, the invention creates a universal therapeutic approach that can be applied to all HD patients. The mismatched oligonucleotides recognize the expanded CAG repeats through their repetitive nature, making the therapy broadly applicable while maintaining allele-specific precision.
3Productivity
If fully-complementary duplex RNA is used, then HTT expression is inhibited, but selectivity for mutant versus wild-type HTT is lost
Solution Approach 1:
The patent modifies the oligonucleotide sequence by introducing 1-5 base mismatches within the CAG repeat binding region. This parameter change fundamentally alters the binding thermodynamics: the mismatched oligonucleotides maintain high binding affinity for mutant HTT mRNA due to the repetitive nature of expanded CAG repeats that can accommodate mismatches, while showing significantly reduced affinity for wild-type HTT mRNA. This parameter modification enables the duplex RNA to maintain high inhibition efficiency for mutant alleles while achieving the necessary selectivity that fully-complementary sequences lack.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for selective inhibition of mutant protein expression over wild-type, minimizing side effects and achieving allele-selective inhibition of HD and other CAG-repeat related diseases, as demonstrated by the use of chemically modified RNAs that retain potency and selectivity in various cell lines.
Implementation Method 1
a double-stranded RNA of 15-30 bases that targets said expanded CAG repeat region of a disease protein mRNA
Data Source
AI summary
The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated.